Skip to content

Advertisement

  • Poster presentation
  • Open Access

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy

  • 1,
  • 2,
  • 2,
  • 1 and
  • 1
Journal of the International AIDS Society201013 (Suppl 4) :P234

https://doi.org/10.1186/1758-2652-13-S4-P234

  • Published:

Keywords

  • Coronary Heart Disease
  • Opportunistic Infection
  • Lifetime Cost
  • Virologic Suppression
  • State Transition Probability

Purpose of the study

Selection of initial antiretroviral therapy (ART) may be informed by factors such as efficacy, adverse effects, and cost. This study assessed the lifetime cost-effectiveness of atazanavir-ritonavir (ATV/r) versus lopinavir-ritonavir (LPV/r) in HIV patients initiating first-line ART.

Methods

A Markov microsimulation model was developed to project lifetime health-related outcomes, costs, quality-adjusted life years (QALYs), and cost-effectiveness of ATV/r versus LPV/r, both with tenofovir-emtricitabine, as first-line ART. Virologic suppression, baseline characteristics, state transition probabilities, cholesterol changes, and adverse effects were based on 96-week CASTLE results. HIV-related mortality, opportunistic infection (OI) and AIDS rates, coronary heart disease (CHD) risk, treatment adherence, costs, and utilities were obtained from published sources. Costs were reported in 2009 US dollars. Sensitivity analyses were conducted to assess the robustness of study results.

Summary of results

Compared with patients initiating LPV/r, patients initiating ATV/r were estimated to have longer time in first-line therapy, fewer cases of AIDS, OI, CHD, and diarrhea, more cases of hyperbilirubinemia (HB), and higher costs. While absolute survival was similar, patients initiating ATV/r were predicted to have longer quality-adjusted survival. Overall, ATV/r added 0.26 QALYs at a cost of $6,826, producing an ICER of $26,421 per QALY gained. Sensitivity analyses indicated that at a willingness to pay threshold of $50,000 per QALY, ATV/r was cost effective 94% of the time. Table 1

Table 1

Health-Related Outcomes

       
 

Time on First-Line Treatment (months)

AIDS cases (per 1000 patient years)

OI cases (per 1000 patient years)

CHD cases (per 1000 patient years)

Diarrhea cases (per 1000 patient years)

HB cases (per 1000 patient years)

Absolute Survival (life years)

LPV/r

70.7

20.054

0.519

5.511

6.262

0.247

18.51

ATV/r

97.3

19.081

0.443

5.437

1.272

6.986

18.52

Cost, QALY, and Cost-Effectiveness

       
 

Cost

Incremental Cost

Quality-Adjusted Survival (QALY)

Incremental QALY

Incremental Cost-Effectiveness

  

LPV/r

$269,160

--

10.761

--

--

  

ATV/r

$275,986

$6,826

11.020

0.258

$26,421

  

Conclusions

Accounting for both lifetime costs and QALYs, ATV/r is cost effective (less than $50,000 per QALY) compared with LPV/r in HIV patients initiating first-line ART.

Authors’ Affiliations

(1)
Partnership for Health Analytic Research, Beverly Hills, USA
(2)
Bristol-Myers Squibb, USP Medical, Plainsboro, USA

Copyright

© Juday et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement